Anzeige
Mehr »
Mittwoch, 31.12.2025 - Börsentäglich über 12.000 News
SILBER-TSUNAMI: $82/Unze - PRINCE SILVER EXPANDIERT BOHRPROGRAMM NACH HISTORISCHEM PREISANSTIEG
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
238 Leser
Artikel bewerten:
(1)

Suvoda LLC: Suvoda IRT named a Leader in Everest Group's RTSM PEAK Matrix

CONSHOHOCKEN, Pa., Dec. 11, 2025 /PRNewswire/ -- Suvoda, a global clinical trial technology company, today announced that its IRT (Interactive Response Technology) software, also known as RTSM (Randomization and Trial Supply Management), has been recognized as a Leader in Everest Group's PEAK Matrix assessment for RTSM technology.

Suvoda

Everest Group's PEAK Matrix is a rigorous, data-driven evaluation of technology providers, benchmarking market impact alongside vision and delivery capability. The assessment includes direct customer interviews, providing insight into real-world performance and user experience. This acknowledgment underscores Suvoda's strong market adoption, innovation, and technical strength in the RTSM space.

"Suvoda demonstrates specialization in managing high-complexity and multi-arm studies, enabled by its low-code/no-code platform, Virtual Partition framework, and strong integration network," said Nisarg Shah, Practice Director at Everest Group. "Its modular architecture, flexible study configuration, and ongoing investments in AI-enabled automation earn it a Leader position in the Everest Group's Life Sciences RTSM Products PEAK Matrix Assessment 2025."

"We are honored to be named a Leader by Everest Group. This recognition reaffirms that Suvoda IRT delivers unparalleled capabilities and speed for randomization and supply management in complex clinical trials," said Jagath Wanninayake, CEO of Suvoda. "It also reflects how we continue to advance our platform, bringing IRT together with our broader suite of products to manage the most critical, time-sensitive moments of each study for our customers."

Suvoda IRT serves as a "command and control center" for clinical trial logistics, enabling sponsors, CROs, and sites to deliver the right treatment to the right patient at the right time. Built on configurable architecture, Suvoda IRT supports even the most complex protocols and features real-time inventory visibility and predictive resupply. The system can quickly adapt to mid-study changes via customization tools built into the Suvoda Platform, which is supported by several issued patents that recognize the company's innovation. Suvoda IRT sets the new standard in the industry, transforming the clinical trial experience for sponsors, CROs, sites, and patients by making the overall journey more intuitive.

To further enhance usability, Suvoda recently introduced Sofia, an AI assistant that simplifies drug supply manager tasks by streamlining data retrieval, monitoring inventory and reviewing visit schedules, and creating data visualizations, all within a conversational interface. The system also delivers real-time analytics through pre-set and ad-hoc reports so that teams can make informed decisions quickly.

For more information, access the Everest Group report on Suvoda IRT here.

About Suvoda
Suvoda is a global clinical trial technology company with a real-time experience platform that empowers sponsors and CROs to make confident decisions and sites and patients to take calm, controlled action. Suvoda delivers interconnected, action-driven software solutions and industry-leading services and support, so that even in the most time-sensitive, mission-critical moments, life-changing studies keep moving forward. Suvoda merged with Greenphire, a leading provider of clinical trial financial management and patient support tools. To learn more, visit suvoda.com and follow Suvoda on LinkedIn.

CONTACT:
Robin Abadía
Director, External Communications
marketing@suvoda.com

Disclaimer
Licensed extracts taken from Everest Group's PEAK Matrix Reports may be used by licensed third parties for use in their own marketing and promotional activities and collateral. Selected extracts from Everest Group's PEAK Matrix reports do not necessarily provide the full context of our research and analysis. All research and analysis conducted by Everest Group's analysts and included in Everest Group's PEAK Matrix reports is independent and no organization has paid a fee to be featured or to influence their ranking. To access the complete research and to learn more about our methodology, please visit Everest Group PEAK Matrix Reports.

Logo - https://mma.prnewswire.com/media/1759317/Suvoda_updated_Logo.jpg

Cision View original content:https://www.prnewswire.com/news-releases/suvoda-irt-named-a-leader-in-everest-groups-rtsm-peak-matrix-302637422.html

© 2025 PR Newswire
Gold & Silber auf Rekordjagd
Kaum eine Entwicklung war 2025 so eindrucksvoll wie der Höhenflug der Edelmetalle. Allen voran Silber: Angetrieben von einem strukturellen Angebotsdefizit, explodierte der Preis und übertrumpfte dabei den „großen Bruder“ Gold. Die Nachfrage aus dem Investmentsektor zieht weiter an, und ein Preisziel von 100 US-Dollar rückt in greifbare Nähe.

Auch Gold markierte neue Meilensteine. Mit dem Durchbruch über 3.000 und 4.000 US-Dollar pro Unze hat sich der übergeordnete Aufwärtstrend eindrucksvoll bestätigt. Rücksetzer bleiben möglich, doch der nächste Zielbereich bei 5.000 US-Dollar ist charttechnisch fest im Blick. Die fundamentalen Treiber sind intakt, eine nachhaltige Trendwende aktuell nicht in Sicht.

Für Anlegerinnen und Anleger bedeutet das: Jetzt ist die Zeit, um gezielt auf starke Produzenten zu setzen. In unserem neuen Spezialreport stellen wir fünf Gold- und Silberaktien vor, die trotz Rallye weiter attraktives Potenzial bieten, mit robusten Fundamentaldaten und starken Projekten in aussichtsreichen Regionen.

Jetzt den kostenlosen Report sichern und von der nächsten Welle im Edelmetall-Boom profitieren!

Dieses exklusive PDF ist nur für kurze Zeit verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.